Shopping Cart 0
Cart Subtotal
AED 0

Klebsiella pneumoniae Infections - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Klebsiella pneumoniae Infections-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2018, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 29 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Klebsiella pneumoniae Infections-Overview 5

Klebsiella pneumoniae Infections-Therapeutics Development 6

Klebsiella pneumoniae Infections-Therapeutics Assessment 15

Klebsiella pneumoniae Infections-Companies Involved in Therapeutics Development 23

Klebsiella pneumoniae Infections-Drug Profiles 36

Klebsiella pneumoniae Infections-Dormant Projects 108

Klebsiella pneumoniae Infections-Discontinued Products 110

Klebsiella pneumoniae Infections-Product Development Milestones 111

Appendix 120


List Of Figure

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 16

Number of Products by Top 10 Targets, H2 2018 21

Number of Products by Stage and Top 10 Targets, H2 2018 21

Number of Products by Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Routes of Administration, H2 2018 25

Number of Products by Stage and Routes of Administration, H2 2018 25

Number of Products by Top 10 Molecule Types, H2 2018 27

Number of Products by Stage and Top 10 Molecule Types, H2 2018 27


List Of Table

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 16

Products under Development by Companies, H2 2018 17

Products under Development by Universities/Institutes, H2 2018 20

Number of Products by Stage and Target, H2 2018 22

Number of Products by Stage and Mechanism of Action, H2 2018 24

Number of Products by Stage and Route of Administration, H2 2018 26

Number of Products by Stage and Molecule Type, H2 2018 28

Klebsiella pneumoniae Infections-Pipeline by ABAC Therapeutics SA, H2 2018 29

Klebsiella pneumoniae Infections-Pipeline by Acies Bio doo, H2 2018 29

Klebsiella pneumoniae Infections-Pipeline by AmpliPhi Biosciences Corp, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by Appili Therapeutics Inc, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by BB200 LLC, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by C3J Therapeutics Inc, H2 2018 31

Klebsiella pneumoniae Infections-Pipeline by ContraFect Corp, H2 2018 31

Klebsiella pneumoniae Infections-Pipeline by Daiichi Sankyo Co Ltd, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by Debiopharm International SA, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by Evaxion Biotech ApS, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018 33

Klebsiella pneumoniae Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018 33

Klebsiella pneumoniae Infections-Pipeline by LegoChem Biosciences Inc, H2 2018 34

Klebsiella pneumoniae Infections-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018 34

Klebsiella pneumoniae Infections-Pipeline by Melinta Therapeutics Inc, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Microbiotix Inc, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Nosopharm SAS, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Novartis AG, H2 2018 36

Klebsiella pneumoniae Infections-Pipeline by Peptilogics Inc, H2 2018 36

Klebsiella pneumoniae Infections-Pipeline by Pfizer Inc, H2 2018 37

Klebsiella pneumoniae Infections-Pipeline by Phico Therapeutics Ltd, H2 2018 37

Klebsiella pneumoniae Infections-Pipeline by Shionogi & Co Ltd, H2 2018 38

Klebsiella pneumoniae Infections-Pipeline by Soligenix Inc, H2 2018 38

Klebsiella pneumoniae Infections-Pipeline by Spero Therapeutics Inc, H2 2018 39

Klebsiella pneumoniae Infections-Pipeline by Summit Therapeutics Plc, H2 2018 39

Klebsiella pneumoniae Infections-Pipeline by Syntiron LLC, H2 2018 40

Klebsiella pneumoniae Infections-Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018 40

Klebsiella pneumoniae Infections-Pipeline by Vaxdyn SL, H2 2018 41

Klebsiella pneumoniae Infections-Pipeline by Venus Medicine Research Center, H2 2018 41

Klebsiella pneumoniae Infections-Dormant Projects, H2 2018 114

Klebsiella pneumoniae Infections-Discontinued Products, H2 2018 116

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Klebsiella pneumoniae Infections Therapeutic Products under Development, Key Players in Klebsiella pneumoniae Infections Therapeutics, Klebsiella pneumoniae Infections Pipeline Overview, Klebsiella pneumoniae Infections Pipeline, Klebsiella pneumoniae Infections Pipeline Assessment


Companies

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

BB200 LLC

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Kyorin Pharmaceutical Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novartis AG

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Klebsiella pneumoniae Infections-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2018, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 29 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 4

Klebsiella pneumoniae Infections-Overview 5

Klebsiella pneumoniae Infections-Therapeutics Development 6

Klebsiella pneumoniae Infections-Therapeutics Assessment 15

Klebsiella pneumoniae Infections-Companies Involved in Therapeutics Development 23

Klebsiella pneumoniae Infections-Drug Profiles 36

Klebsiella pneumoniae Infections-Dormant Projects 108

Klebsiella pneumoniae Infections-Discontinued Products 110

Klebsiella pneumoniae Infections-Product Development Milestones 111

Appendix 120


List Of Figure

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 13

Number of Products under Development by Universities/Institutes, H2 2018 16

Number of Products by Top 10 Targets, H2 2018 21

Number of Products by Stage and Top 10 Targets, H2 2018 21

Number of Products by Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 23

Number of Products by Routes of Administration, H2 2018 25

Number of Products by Stage and Routes of Administration, H2 2018 25

Number of Products by Top 10 Molecule Types, H2 2018 27

Number of Products by Stage and Top 10 Molecule Types, H2 2018 27


List Of Table

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2018 12

Number of Products under Development by Companies, H2 2018 14

Number of Products under Development by Universities/Institutes, H2 2018 16

Products under Development by Companies, H2 2018 17

Products under Development by Universities/Institutes, H2 2018 20

Number of Products by Stage and Target, H2 2018 22

Number of Products by Stage and Mechanism of Action, H2 2018 24

Number of Products by Stage and Route of Administration, H2 2018 26

Number of Products by Stage and Molecule Type, H2 2018 28

Klebsiella pneumoniae Infections-Pipeline by ABAC Therapeutics SA, H2 2018 29

Klebsiella pneumoniae Infections-Pipeline by Acies Bio doo, H2 2018 29

Klebsiella pneumoniae Infections-Pipeline by AmpliPhi Biosciences Corp, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by Appili Therapeutics Inc, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by BB200 LLC, H2 2018 30

Klebsiella pneumoniae Infections-Pipeline by C3J Therapeutics Inc, H2 2018 31

Klebsiella pneumoniae Infections-Pipeline by ContraFect Corp, H2 2018 31

Klebsiella pneumoniae Infections-Pipeline by Daiichi Sankyo Co Ltd, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by Debiopharm International SA, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by Evaxion Biotech ApS, H2 2018 32

Klebsiella pneumoniae Infections-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018 33

Klebsiella pneumoniae Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018 33

Klebsiella pneumoniae Infections-Pipeline by LegoChem Biosciences Inc, H2 2018 34

Klebsiella pneumoniae Infections-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018 34

Klebsiella pneumoniae Infections-Pipeline by Melinta Therapeutics Inc, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Microbiotix Inc, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Nosopharm SAS, H2 2018 35

Klebsiella pneumoniae Infections-Pipeline by Novartis AG, H2 2018 36

Klebsiella pneumoniae Infections-Pipeline by Peptilogics Inc, H2 2018 36

Klebsiella pneumoniae Infections-Pipeline by Pfizer Inc, H2 2018 37

Klebsiella pneumoniae Infections-Pipeline by Phico Therapeutics Ltd, H2 2018 37

Klebsiella pneumoniae Infections-Pipeline by Shionogi & Co Ltd, H2 2018 38

Klebsiella pneumoniae Infections-Pipeline by Soligenix Inc, H2 2018 38

Klebsiella pneumoniae Infections-Pipeline by Spero Therapeutics Inc, H2 2018 39

Klebsiella pneumoniae Infections-Pipeline by Summit Therapeutics Plc, H2 2018 39

Klebsiella pneumoniae Infections-Pipeline by Syntiron LLC, H2 2018 40

Klebsiella pneumoniae Infections-Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018 40

Klebsiella pneumoniae Infections-Pipeline by Vaxdyn SL, H2 2018 41

Klebsiella pneumoniae Infections-Pipeline by Venus Medicine Research Center, H2 2018 41

Klebsiella pneumoniae Infections-Dormant Projects, H2 2018 114

Klebsiella pneumoniae Infections-Discontinued Products, H2 2018 116

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Klebsiella pneumoniae Infections Therapeutic Products under Development, Key Players in Klebsiella pneumoniae Infections Therapeutics, Klebsiella pneumoniae Infections Pipeline Overview, Klebsiella pneumoniae Infections Pipeline, Klebsiella pneumoniae Infections Pipeline Assessment


Companies

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

BB200 LLC

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Kyorin Pharmaceutical Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Microbiotix Inc

Nosopharm SAS

Novartis AG

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Plc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center